Principal Financial Group Inc Ultragenyx Pharmaceutical Inc. Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q4 2024

A detailed history of Principal Financial Group Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 89,955 shares of RARE stock, worth $3.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
89,955
Holding current value
$3.83 Million
% of portfolio
0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 31, 2025
BUY
$42.07 - $57.72 $3.78 Million - $5.19 Million
89,955 New
89,955 $3.78 Million
Q3 2024

Oct 31, 2024
BUY
$40.21 - $59.36 $3.06 Million - $4.52 Million
76,150 Added 740.04%
86,440 $4.8 Million
Q2 2024

Jul 29, 2024
SELL
$37.42 - $51.61 $212,807 - $293,506
-5,687 Reduced 35.59%
10,290 $422,000
Q1 2024

Apr 29, 2024
SELL
$43.02 - $53.69 $31,404 - $39,193
-730 Reduced 4.37%
15,977 $745,000
Q4 2023

Feb 07, 2024
SELL
$31.73 - $49.19 $29,159 - $45,205
-919 Reduced 5.21%
16,707 $798,000
Q3 2023

Nov 02, 2023
BUY
$34.92 - $46.66 $24,583 - $32,848
704 Added 4.16%
17,626 $628,000
Q2 2023

Aug 07, 2023
SELL
$37.35 - $52.15 $373 - $521
-10 Reduced 0.06%
16,922 $780,000
Q1 2023

May 09, 2023
SELL
$36.99 - $48.71 $49,492 - $65,173
-1,338 Reduced 7.32%
16,932 $678,000
Q4 2022

Feb 09, 2023
BUY
$33.72 - $46.33 $85,851 - $117,956
2,546 Added 16.19%
18,270 $846,000
Q3 2022

Nov 09, 2022
SELL
$39.96 - $66.14 $29,370 - $48,612
-735 Reduced 4.47%
15,724 $651,000
Q2 2022

Aug 10, 2022
BUY
$45.8 - $85.4 $103,691 - $193,345
2,264 Added 15.95%
16,459 $982,000
Q1 2022

May 09, 2022
SELL
$62.2 - $84.4 $12,937 - $17,555
-208 Reduced 1.44%
14,195 $1.03 Million
Q4 2021

Feb 09, 2022
SELL
$73.71 - $87.86 $393,021 - $468,469
-5,332 Reduced 27.02%
14,403 $1.21 Million
Q3 2021

Nov 09, 2021
SELL
$77.92 - $102.4 $193,787 - $254,668
-2,487 Reduced 11.19%
19,735 $1.78 Million
Q2 2021

Aug 10, 2021
SELL
$92.19 - $115.71 $5.31 Million - $6.66 Million
-57,596 Reduced 72.16%
22,222 $2.12 Million
Q1 2021

May 10, 2021
BUY
$106.9 - $167.73 $5.5 Million - $8.63 Million
51,458 Added 181.45%
79,818 $9.09 Million
Q4 2020

Feb 08, 2021
BUY
$84.4 - $177.39 $622,028 - $1.31 Million
7,370 Added 35.11%
28,360 $3.93 Million
Q3 2020

Nov 06, 2020
SELL
$72.98 - $90.0 $70,863 - $87,390
-971 Reduced 4.42%
20,990 $1.73 Million
Q2 2020

Aug 05, 2020
BUY
$46.91 - $78.22 $278,504 - $464,392
5,937 Added 37.05%
21,961 $1.72 Million
Q1 2020

May 12, 2020
BUY
$33.8 - $62.9 $8,314 - $15,473
246 Added 1.56%
16,024 $712,000
Q4 2019

Feb 05, 2020
SELL
$36.08 - $45.83 $54,156 - $68,790
-1,501 Reduced 8.69%
15,778 $674,000
Q3 2019

Nov 13, 2019
BUY
$42.5 - $63.11 $69,870 - $103,752
1,644 Added 10.51%
17,279 $739,000
Q2 2019

Aug 12, 2019
BUY
$54.93 - $74.36 $36,089 - $48,854
657 Added 4.39%
15,635 $993,000
Q1 2019

May 10, 2019
BUY
$39.87 - $69.36 $61,320 - $106,675
1,538 Added 11.44%
14,978 $1.04 Million
Q4 2018

Feb 14, 2019
SELL
$38.89 - $77.3 $124,992 - $248,442
-3,214 Reduced 19.3%
13,440 $584,000
Q3 2018

Nov 14, 2018
BUY
$71.81 - $90.15 $169,256 - $212,483
2,357 Added 16.49%
16,654 $1.27 Million
Q2 2018

Aug 13, 2018
BUY
$48.54 - $85.31 $59,024 - $103,736
1,216 Added 9.3%
14,297 $0
Q1 2018

May 14, 2018
SELL
$44.33 - $58.52 $2,704 - $3,569
-61 Reduced 0.46%
13,081 $667,000
Q4 2017

Feb 13, 2018
SELL
$43.54 - $57.32 $2.58 Million - $3.4 Million
-59,247 Reduced 81.85%
13,142 $609,000
Q3 2017

Nov 02, 2017
BUY
$49.79 - $66.32 $3.6 Million - $4.8 Million
72,389
72,389 $3.86 Million

Others Institutions Holding RARE

# of Institutions
344
Shares Held
86.6M
Call Options Held
675K
Put Options Held
846K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.98B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email